Dr. Ahmad Tarhini on Ipilimumab vs Interferon-α2b for Resected High-Risk Melanoma

Video

Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019.

Cancer Network spoke with Ahmad Tarhini, MD, PhD, a medical oncologist with at Emory Winship Cancer Institute, about a phase III study of adjuvant ipilimumab versus high-dose interferon-a2b for treating resected high-risk melanoma. The results of the trial were presented at ASCO 2019.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.